Vitamin K2 in bone metabolism and osteoporosis

Alternative Medicine Review

Volumn 10, Issue 1, 2005, Pages 24-35

  Plaza, Steven M ^a,b,c   Lamson, Davis W ^a,d  

^a BASTYR UNIVERSITY   (United States)

^b Center for Traditional Medicine   (United States)

^c Tahoma Clinic ^*  (United States)

^d Tahoma Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITRIOL; ETIDRONIC ACID; FARNOQUINONE; GLUCOCORTICOID; LEUPRORELIN; PHENYTOIN; PHYTOMENADIONE; PREDNISOLONE; RISEDRONIC ACID;

ADULT; AGED; BILIARY CIRRHOSIS; BONE METABOLISM; CHILD; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PARKINSON DISEASE; POSTMENOPAUSE OSTEOPOROSIS; RAT; REVIEW; SIDE EFFECT; STROKE;

ANIMALS; BONE DISEASES, METABOLIC; DISEASE MODELS, ANIMAL; HUMANS; OSTEOPOROSIS; VITAMIN K 2;

EID: 15444379313     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Asakura H, Myou S, Ontachi Y, et al. Vitamin K administration to elderly patients with osteoporosis induces no hemostatic activation, even in those with suspected vitamin K deficiency. Osteoporos Int 2001;12:996-1000.
2. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-882.
3. Shepherd AJ. An overview of osteoporosis. Altern Ther Health Med 2004;10:26-33;quiz 34,92.
4. Kenny AM, Joseph C, Taxel P, Prestwood KM. Osteoporosis in older men and women. Conn Med 2003;67:481-486.
5. South-Paul JE. Osteoporosis: part I. Evaluation and assessment. Am Fam Physician 2001;63:897-904,908.
6. South-Paul JE. Osteoporosis: part II. Nonpharmacologic and pharmacologic treatment. Am Fam Physician 2001;63:1121-1128.
7. Rubin CD. Treatment considerations in the management of age-related osteoporosis. Am J Med Sci 1999;318:158-170.
8. Gaby A. Preventing and Reversing Osteoporosis. Every Woman's Essential Guide. Rocklin, CA: Prima Publications; 1994.
9. Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology 2001;120:636-651.
10. Green PH, Jabri B. Coeliac disease. Lancet 2003;362:383-391.
11. Maki M, Collin P. Coeliac disease. Lancet 1997;349:1755-1759.
12. Moreno ML, Vazquez H, Mazure R, et al. Stratification of bone fracture risk in patients with celiac disease. Clin Gastroenterol Hepatol 2004;2:127-134.
13. Booth SL, Mayer J. Warfarin use and fracture risk. Nutr Rev 2000;58:20-22.
14. Simon RR, Beaudin SM, Johnston M, et al. Long-term treatment with sodium warfarin results in decreased femoral bone strength and cancellous bone volume in rats. Thromb Res 2002;105:353-358.
15. von Tirpitz C, Reinshagen M. Management of osteoporosis in patients with gastrointestinal diseases. Eur J Gastroenterol Hepatol 2003;15:869-876.
16. Bottaro G, Fichera A, Ricca O, et al. Effect of the therapy with vitamin K on coagulation factors in celiac disease in children. Pediatr Med Chir 1986;8:551-554. [Article in Italian]
17. Rodesch P, Cadranel S, Winckler M, Loeb H. Hypovitaminosis K in coeliac disease. Acta Paediatr Belg 1976;29:123-124.
18. Shearer MJ, Mallinson CN, Webster GR, Barkhan P. Absorption of tritiated vitamin K1 in patients with fat malabsorption. Gut 1970;11:1063-1064.
19. Thomson RH. Naturally Occurring Quinones. New York, NY: Academic Press; 1971.
20. Davidson RT, Foley AL, Engelke JA, Suttie JW. Conversion of dietary phylloquinone to tissue menaquinone-4 in rats is not dependent on gut bacteria. J Nutr 1998;128:220-223.
21. Thijssen HH, Drittij-Reijnders MJ. Vitamin K status in human tissues: tissue-specific accumulation of phylloquinone and menaquinone-4. Br J Nutr 1996;75:121-127.
22. Seegers WH, Bang NU. Blood Clotting Enzymology. New York, NY: Academic Press; 1967.
23. Lamson DW, Plaza SM. The anticancer effects of vitamin K. Altern Med Rev 2003;8:303-318.
24. Billeter M, Bolliger W, Martius C. Studies on the transformation of the K vitamins given orally by exchange of side chains and the role of intestinal bacteria therein. Biochem Z 1964;340:290-303. [Article in German]
25. Budavari S. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals. Rahway, NJ; Merck; 1989.
26. Taggart WV, Matschiner JT. Metabolism of menadione-6,7-3H in the rat. Biochemistry 1969;8:1141-1146.
27. Ushiroyama T, Ikeda A, Ueki M. Effect of continuous combined therapy with vitamin K(2) and vitamin D(3) on bone mineral density and coagulofibrinolysis function in postmenopausal women. Maturitas 2002;41:211-221.
28. Hauschka PV, Lian JB, Gallop PM. Direct identification of the calcium-binding amino acid, gamma-carboxyglutamate, in mineralized tissue. Proc Natl Acad Sci U S A 1975;72:3925-3929.
29. Hara K, Akiyama Y, Nakamura T, et al. The inhibitory effect of vitamin K2 (menatetrenone) on bone resorption may be related to its side chain. Bone 1995;16:179-184.
30. Price PA, Parthemore JG, Deftos LJ. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. J Clin Invest 1980;66:878-883.
31. Booth SL, Suttie JW. Dietary intake and adequacy of vitamin K. J Nutr 1998;128:785-788.
32. Binkley NC, Krueger DC, Engelke JA, et al. Vitamin K supplementation reduces serum concentrations of under-gamma-carboxylated osteocalcin in healthy young and elderly adults. Am J Clin Nutr 2000;72:1523-1528.
33. Bitensky L, Hart JP, Catterall A, et al. Circulating vitamin K levels in patients with fractures. J Bone Joint Surg Br 1988;70:663-664.
34. Akiyama Y, Hara K, Matsumoto A, et al. Comparison of intestinal absorption of vitamin K2 (menaquinone) homologues and their effects on blood coagulation in rats with hypoprothrombinaemia. Biochem Pharmacol 1995;49:1801-1807.
35. Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000;15:515-521.
36. Orimo H, Shiraki M, Tomita A, et al. Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: a double-blind placebo-controlled study. J Bone Miner Metab 1998;16:106-112.
37. Ronden JE, Groenen-van Dooren MM, Hornstra G, Vermeer C. Modulation of arterial thrombosis tendency in rats by vitamin K and its side chains. Atherosclerosis 1997;132:61-67.
38. Crowther MA, Donovan D, Harrison L, et al. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost 1998;79:1116-1118.
39. Yamaguchi M, Taguchi H, Gao YH, et al. Effect of vitamin K2 (menaquinone-7) in fermented soybean (natto) on bone loss in ovariectomized rats. J Bone Miner Metab 1999;17:23-29.
40. Koshihara Y, Hoshi K, Ishibashi H, Shiraki M. Vitamin K2 promotes 1alpha,25(OH)2 vitamin D3-induced mineralization in human periosteal osteoblasts. Calcif Tissue Int 1996;59:466-473.
41. Koshihara Y, Hoshi K. Vitamin K2 enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro. J Bone Miner Res 1997;12:431-438.
42. Akiyama Y, Hara K, Tajima T, et al. Effect of vitamin K2 (menatetrenone) on osteoclast-like cell formation in mouse bone marrow cultures. Eur J Pharmacol 1994;263:181-185.
43. Hara K, Akiyama Y, Tajima T, Shiraki M. Menatetrenone inhibits bone resorption partly through inhibition of PGE2 synthesis in vitro. J Bone Miner Res 1993;8:535-542.
44. Hiruma Y, Nakahama K, Fujita H, Morita I. Vitamin K2 and geranylgeraniol, its side chain component, inhibited osteoclast formation in a different manner. Biochem Biophys Res Commun 2004;314:24-30.
45. Koshihara Y, Hoshi K, Okawara R, et al. Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. J Endocrinol 2003;176:339-348.
46. Akiyama Y, Hara K, Kobayashi M, et al. Inhibitory effect of vitamin K2 (menatetrenone) on bone resorption in ovariectomized rats: a histomorphometric and dual energy X-ray absorptiometric study. Jpn J Pharmacol 1999;80:67-74.
47. Sato T, Ohtani Y, Yamada Y, et al. Difference in the metabolism of vitamin K between liver and bone in vitamin K-deficient rats. Br J Nutr 2002;87:307-314.
48. Iwamoto J, Yeh JK, Takeda T. Effect of vitamin K2 on cortical and cancellous bones in orchidectomized and/or sciatic neurectomized rats. J Bone Miner Res 2003;18:776-783.
49. Iwasaki Y, Yamato H, Murayama H, et al. Menatetrenone prevents osteoblast dysfunction in unilateral sciatic neurectomized rats. Jpn J Pharmacol 2002;90:88-93.
50. Hara K, Akiyama Y, Ohkawa I, Tajima T. Effects of menatetrenone on prednisolone-induced bone loss in rats. Bone 1993;14:813-818.
51. Mawatari T, Miura H, Higaki H, et al. Effect of vitamin K2 on three-dimensional trabecular microarchitecture in ovariectomized rats. J Bone Miner Res 2000;15:1810-1817.
52. Shiraishi A, Higashi S, Masaki T, et al. A comparison of alfacalcidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteoporosis. Calcif Tissue Int 2002;71:69-79.
53. Binkley N, Krueger D, Engelke J, et al. Vitamin K supplementation does not affect ovariectomy-induced bone loss in rats. Bone 2002;30:897-900.
54. Akiyama Y, Hara K, Ohkawa I, Tajima T. Effects of menatetrenone on bone loss induced by ovariectomy in rats. Jpn J Pharmacol 1993;62:145-153.
55. Hara K, Kobayashi M, Akiyama Y. Effect of combined treatment with vitamin K2 and 1 alpha-(OH)-vitamin D3 on bone loss in ovariectomized rats. Nippon Yakurigaku Zasshi 2001;118:231-240. [Article in Japanese]
56. Iwamoto J, Takeda T, Yeh JK, et al. Effect of vitamin K2 on cortical and cancellous bones in orchidectomized young rats. Maturitas 2003;44:19-27.
57. Kato S, Mano T, Kobayashi T, et al. A calcium-deficient diet caused decreased bone mineral density and secondary elevation of estrogen in aged male rats - effect of menatetrenone and elcatonin. Metabolism 2002;51:1230-1234.
58. Meunier PJ, Dempster DW, Edouard C, et al. Bone histomorphometry in corticosteroid-induced osteoporosis and Cushing's syndrome. Adv Exp Med Biol 1984;171:191-200.
59. Jowsey J, Riggs BL. Bone formation in hypercortisonism. Acta Endocrinol (Copenh) 1970;63:21-28.
60. Hara K, Kobayashi M, Akiyama Y. Vitamin K2 (menatetrenone) inhibits bone loss induced by prednisolone partly through enhancement of bone formation in rats. Bone 2002;31:575-581.
61. Kokai Y, Wada T, Oda T, et al. Overexpression of granulocyte colony-stimulating factor induces severe osteopenia in developing mice that is partially prevented by a diet containing vitamin K2 (menatetrenone). Bone 2002;30:880-885.
62. Valimaki MJ, Tiihonen M, Laitinen K, et al. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994;9:631-637.
63. Onodera K, Takahashi A, Wakabayashi H, et al. Effects of menatetrenone on the bone and serum levels of vitamin K2 (menaquinone derivatives) in osteopenia induced by phenytoin in growing rats. Nutrition 2003;19:446-450.
64. Orimo H, Shiraki M, Fiujita T, et al. Clinical evaluation of menatetrenone in the treatment of involutional osteoporosis: a double-blind multicenter comparative study with 1-alpha-dihydroxyvitamin D3. J Bone Miner Res 1992;7: S122.
65. Iwamoto J, Takeda T, Ichimura S. Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis. J Orthop Sci 2000;5:546-551.
66. Iwamoto I, Kosha S, Noguchi S, et al. A longitudinal study of the effect of vitamin K2 on bone mineral density in postmenopausal women a comparative study with vitamin D3 and estrogen-progestin therapy. Maturitas 1999;31:161-164.
67. Iwamoto J, Takeda T, Ichimura S. Treatment with vitamin D3 and/or vitamin K2 for postmenopausal osteoporosis. Keio J Med 2003;52:147-150.
68. Iwamoto J, Takeda T, Ichimura S. Combined treatment with vitamin K2 and bisphosphonate in postmenopausal women with osteoporosis. Yonsei Med J 2003;44:751-756.
69. Johnell O, Melton LJ 3rd, Atkinson EJ, et al. Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. Age Ageing 1992;21:32-38.
70. Kao CH, Chen CC, Wang SJ, et al. Bone mineral density in patients with Parkinson's disease measured by dual photon absorptiometry. Nucl Med Commun 1994;15:173-177.
71. Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology 1997;49:1273-1278.
72. Sato Y, Honda Y, Kaji M, et al. Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency. Bone 2002;31:114-118.
73. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-955.
74. Dawson-Hughes B. Bone loss accompanying medical therapies. N Engl J Med 2001;345:989-991.
75. Somekawa Y, Chigughi M, Harada M, Ishibashi T. Use of vitamin K2 (menatetrenone) and 1,25-dihydroxyvitamin D3 in the prevention of bone loss induced by leuprolide. J Clin Endocrinol Metab 1999;84:2700-2704.
76. Rehman Q, Lane NE. Effect of glucocorticoids on bone density. Med Pediatr Oncol 2003;41:212-216.
77. Yonemura K, Kimura M, Miyaji T, Hishida A. Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis. Calcif Tissue Int 2000;66:123-128.
78. Yonemura K, Fukasawa H, Fujigaki Y, Hishida A. Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine. Am J Kidney Dis 2004;43:53-60.
79. Inoue T, Sugiyama T, Matsubara T, et al. Inverse correlation between the changes of lumbar bone mineral density and serum undercarboxylated osteocalcin after vitamin K2 (menatetrenone) treatment in children treated with glucocorticoid and alfacalcidol. Endocr J 2001;48:11-18.
80. Nishiguchi S, Shimoi S, Kurooka H, et al. Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. J Hepatol 2001;35:543-545.
81. Sato Y, Kuno H, Kaji M, et al. Increased bone resorption during the first year after stroke. Stroke 1998;29:1373-1377.
82. Sato Y, Honda Y, Kuno H, Oizumi K. Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. Bone 1998;23:291-296.
83. Sugiyama T, Tanaka H, Kawai S. Clinical vignette. Vitamin K plus vitamin D treatment of bone problems in a child with skeletal unloading. J Bone Miner Res 1999;14:1466-1467.
84. Vermeer C, Ulrich MM. The effect of microgravity on plasma-osteocalcin. Adv Space Res 1986;6:139-142.
85. Iwasaki Y, Yamato H, Murayama H, et al. Maintenance of trabecular structure and bone volume by vitamin K(2) in mature rats with long-term tail suspension. J Bone Miner Metab 2002;20:216-222.
86. Vermeer C, Wolf J, Craciun AM, Knapen MH. Bone markers during a 6-month space flight: effects of vitamin K supplementation. J Gravit Physiol 1998;5:65-69.
87. Schneider M, Fisher M, Weinerman S, Lesser M. Correlates of low bone density in females with anorexia nervosa. Int J Adolesc Med Health 2002;14:297-306.
88. Iketani T, Kiriike N, Murray, et al. Effect of menatetrenone (vitamin K2) treatment on bone loss in patients with anorexia nervosa. Psychiatry Res 2003;117:259-269.
89. Kubovic M, Prazic M, Atanackovic D. Analgetic property of vitamin K. Proc Soc Exp Biol Med 1955;90:660-662.
90. Plaza SM, Lamson DW. Mitochondrial aspects of vitamin K. Article in preparation.
91. Habu D, Shiomi S, Tamori A, et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004;292:358-361.
92. Plaza SM, Lamson DW. Vitamin K in myelin metabolism. Article in preparation.